Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...
Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.
The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...
Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results